Phathom Pharmaceuticals
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders. Phathom has assembled a leading team of seasoned gastrointestinal and pharmaceutical industry experts with proven experience developing and commercializing highly innovative therapies.
Domain
phathompharma.com
Country
United StatesIndustry
BiotechnologyEmployees
251-500
Last Funding
$130.0M
Founded
2017
Tech Stack (21 technologies)
Frequently Asked Questions
What technologies does Phathom Pharmaceuticals use?+
Phathom Pharmaceuticals uses 21 technologies including Bootstrap, Cookiebot, Photo Gallery.
What industry is Phathom Pharmaceuticals in?+
Phathom Pharmaceuticals operates in the Biotechnology industry.
Where is Phathom Pharmaceuticals based?+
Phathom Pharmaceuticals is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026